Patents Assigned to Alliance Pharmaceutical Corp.
-
Patent number: 8748497Abstract: The present invention is directed to a stable fluorocarbon emulsion having a continuous aqueous phase and discontinuous fluorocarbon phase comprising two fluorocarbons and surprisingly demonstrates that perfluorodecyl bromide is as effective in stabilizing perfluorooctyl bromide emulsions of certain concentrations than much more highly concentrated perfluorooctyl bromide/perfluorodecyl bromide emulsions without the significant problems experienced in higher concentrated emulsions such as longer organ retention times, formation of PFDB crystals, larger emulsion particles, manufacturing problems and inability of repeat dosing inherent with higher concentrations of perfluorodecyl bromide.Type: GrantFiled: May 22, 2007Date of Patent: June 10, 2014Assignee: Alliance Pharmaceutical Corp.Inventors: Jeffry Weers, David Klein, Cindy Johnson
-
Patent number: 6743172Abstract: A system and method is described for determining and graphically displaying oxygenation states of a patient in real time. The system is non-invasive and can display information to a physician that is intuitive. Various display objects are described for illustrating the output of oxygenation values. The display objects reflect the in vivo physiology that they measure, thus making interpretation of the measured values very intuitive.Type: GrantFiled: November 3, 2000Date of Patent: June 1, 2004Assignees: Alliance Pharmaceutical Corp., The Trustees of Dartmouth CollegeInventor: George T. Blike
-
Patent number: 6679859Abstract: A method of ameliorating tissue damage resulting from hypoxia or ischemia by administering systemically a synthetic oxygen carrier to an individual having or suspected of having blood vessel obstruction is disclosed. A synthetic oxygen carrier in a physiologically acceptable vehicle, wherein the synthetic oxygen carrier comprises submicron sized particles capable of passing through emboli-obstructed blood vessels is also disclosed.Type: GrantFiled: July 31, 2000Date of Patent: January 20, 2004Assignee: Alliance Pharmaceutical Corp.Inventors: Peter E. Keipert, N. Simon Faithfull, Stephen F. Flaim, Gwen H. Rosenberg
-
Publication number: 20020103165Abstract: In accordance with the present invention there are provided novel Spray-Dried Lipid Microparticles (SDLM) that are comprised of lipid, a ligand and agent. The ligand is specific for a cell surface receptor, thereby enabling targeting of the agent to cells bearing receptors specific for the targeting ligand. In invention embodiments wherein the receptor internalizes upon ligand binding, there are provided compositions and methods for the introduction of agent into specifically targeted cells. In a particular embodiment, the ligand is specific for antigen presenting cells (APC) and the agent is a defined antigen. In this manner, immune responses can be induced against specific antigens, including those which are normally not very antigenic due to the fact that they are inefficiently internalized by APC.Type: ApplicationFiled: February 29, 2000Publication date: August 1, 2002Applicant: ALLIANCE PHARMACEUTICAL CORP.,Inventors: Adrian Bot, Luis Dellamary, Dan Smith, Catherine M. Woods
-
Publication number: 20020098151Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760−x) mm Hg at 37 C., where x is the vapor pressure of the second gas at 37 C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37 C.Type: ApplicationFiled: December 19, 2001Publication date: July 25, 2002Applicant: Alliance Pharmaceutical Corp.Inventors: Ernest G. Schutt, David P. Evitts, Rene Alta Kinner, Charles David Anderson, Jeffry G. Weers
-
Patent number: 6420436Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.Type: GrantFiled: June 19, 1998Date of Patent: July 16, 2002Assignee: Alliance Pharmaceutical Corp.Inventor: W. Dean Kirkland
-
Patent number: 6390977Abstract: Systems are methods described for calculating, in real-time, various oxygenation parameters including total oxygen transport, mixed venous blood oxygen tension and mixed venous blood oxyhemoglobin saturation in a patient. The system preferably uses a computer, an arterial pressure line and a blood chemistry monitor to assist a physician in accurately determining when to give a patient a blood transfusion or otherwise alter the clinical management of that patient.Type: GrantFiled: December 11, 1996Date of Patent: May 21, 2002Assignee: Alliance Pharmaceutical Corp.Inventors: Nicholas Simon Faithfull, Glenn Rhoades
-
Publication number: 20020051750Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760−x) mm Hg at 37° C., where x is the vapor pressure of the second gas at 37° C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37° C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; kits for preparing microbubbles; and methods for using such microbubbles as ultrasound contrast agents.Type: ApplicationFiled: May 21, 2001Publication date: May 2, 2002Applicant: Alliance Pharmaceutical Corp.Inventors: Ernest G. Schutt, David P. Evitts, Rene Alta Kinner, Charles David Anderson, Jeffry G. Weers
-
Publication number: 20020048602Abstract: The present invention provides a composition comprising one or more constitutive polymers and modifier polymers and/or hydrophilic co-surfactants useful for reducing adhesions or delivering bioactive agents. Methods for preventing and/or reducing post-surgical adhesions or delivering bioactive agents are also provided.Type: ApplicationFiled: August 15, 2001Publication date: April 25, 2002Applicant: Alliance Pharmaceutical Corp.Inventors: Stephen G. Flore, Luis A. Dellamary, Lorraine E. Reeve, Jeffry G. Weers
-
Patent number: 6372195Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760−x) mm Hg at 37° C., where x is the vapor pressure of the second gas at 37° C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37° C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; kits for preparing microbubbles; and methods for using such microbubbles as ultrasound contrast agents.Type: GrantFiled: January 17, 1997Date of Patent: April 16, 2002Assignee: Alliance Pharmaceutical Corp.Inventors: Ernest G. Schutt, David P. Evitts, Rene Alta Kinner, Charles David Anderson, Jeffry G. Weers
-
Patent number: 6368613Abstract: Methods for the diagnosis and treatment of articular disorders comprising the use of fluorocarbons are disclosed. The methods provide for the introduction of a fluorocarbon into an articular region to replace or augment natural synovial fluid. The introduced fluorocarbons, which may be in various forms including liquids, gels or emulsions, provide articular lubrication and cushioning which is effective for the treatment of disorders such as osteoarthritis and rheumatoid arthritis. Additionally, the methods of the present invention may be used to provide high resolution articular images, reduce articular inflammation and introduce bioactive agents to the articular region.Type: GrantFiled: December 21, 1998Date of Patent: April 9, 2002Assignee: Alliance Pharmaceutical Corp.Inventors: Mark A. Walters, Ronald M. Hopkins, David H. Klein
-
Patent number: 6361792Abstract: Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.Type: GrantFiled: December 7, 1998Date of Patent: March 26, 2002Assignee: Alliance Pharmaceutical Corp.Inventor: David M. Long, Jr.
-
Patent number: 6359006Abstract: New fluorinated derivatives useful as surfactants or in the transport of drug or markers, or in drug targeting, and preparations containing the derivatives, for medical, cosmetic and veterinary uses, having the formula: wherein RF is a fluorinated radical, X is a linear or branched alkylene, R1 is H or CH3, R2 is a radical having at least one OH group, R3 is a radical derived from an amino acid or a peptide, 1≦n≦50 and 0≦m≦200 with 0.2≦n/n+m≦1. These derivatives can be used as prodrugs or in formulating pharmaceutical, cosmetic and veterinary preparations, in biology and medicine, notably in compositions acting as carriers of oxygen and other gases, of contrast agents, or as carriers of substances used in therapy, or as carriers of markers.Type: GrantFiled: June 28, 1999Date of Patent: March 19, 2002Assignee: Alliance Pharmaceutical Corp.Inventors: Andre A. Pavia, Bernard Pucci, Jean G. Riess, Leila Zarif
-
Patent number: 6289892Abstract: The present invention includes a method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the step of introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon liquid, the amount not exceeding the functional residual capacity of the lung of the patient upon exhalation taking into account any positive and expiratory pressure applied to the patient's lung. The method may also comprise the additional step of providing an oxygen-containing breathing gas to the patient while the fluorocarbon liquid is in the lung.Type: GrantFiled: March 9, 2000Date of Patent: September 18, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: Nicholas Simon Faithfull, Jeffry Greg Weers
-
Patent number: 6287539Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760−x) mm Hg at 37° C., where x is the vapor pressure of the second gas at 37° C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37° C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; methods and kits for preparing microbubbles; and methods for using such microbubbles as contrast agents.Type: GrantFiled: May 5, 1997Date of Patent: September 11, 2001Assignee: Alliance Pharmaceuticals Corp.Inventors: Ernest G. Schutt, Charles David Anderson, David P. Evitts
-
Patent number: 6280704Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ration of from about 1:100 to abut 1000:1, and wherein the first gas has a vapor pressure of at least about (760−X) mm Hg at 37° C., where x is the vapor pressure of the second gas at 37° C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37° C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; methods and kits for preparing microbubbles; and methods for using such microbubbles as contrast agents.Type: GrantFiled: December 8, 1997Date of Patent: August 28, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: Ernest G. Schutt, Charles David Anderson, David P. Evitts
-
Patent number: 6280705Abstract: A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.Type: GrantFiled: January 26, 1998Date of Patent: August 28, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: Leo A. Trevino, Ernest George Schutt, David H. Klein, Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov
-
Patent number: 6280745Abstract: The present invention provides a composition comprising one or more constitutive polymers and modifier polymers and/or hydrophilic co-surfactants useful for reducing adhesions or delivering bioactive agents. Methods for preventing and/or reducing post-surgical adhesions or delivering bioactive agents are provided.Type: GrantFiled: June 22, 2000Date of Patent: August 28, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: Stephen G. Flore, Luis A. Dellamary, Lorraine E. Reeve, Jeffry G. Weers
-
Patent number: 6258339Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760−x) mm Hg at 37° C., where x is the vapor pressure of the second gas at 37° C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37° C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; kits for preparing microbubbles; and methods for using such microbubbles as ultrasound contrast agents.Type: GrantFiled: May 5, 1997Date of Patent: July 10, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: Ernest G. Schutt, David P. Evitts, Rene Alta Kinner, Charles David Anderson, Jeffry G. Weers
-
Patent number: 6242472Abstract: Methods of delivering a therapeutic or diagnostic agent in a perfluorochemical liquid carrier are provided. In preferred embodiments, the disclosed methods use compositions in the form of an emulsion or a dispersion for delivery of a biological agent to the pulmonary air passages.Type: GrantFiled: July 2, 1998Date of Patent: June 5, 2001Assignee: Alliance Pharmaceutical Corp.Inventors: K. Michael Sekins, Thomas H. Shaffer, Marla R. Wolfson